PCOS Hair Loss: A Sign of High Androgens, Not a Fertility Problem

No. Scalp thinning is a sign that androgen levels or androgen sensitivity are raised, and raised androgens are one of the three criteria used to diagnose PCOS. The other criterion that matters for conceiving is irregular or absent ovulation. Both can come from the same hormonal picture, but the hair is not doing anything to your ovaries, and how much hair you have lost does not tell you how hard it will be to conceive.

The 2023 International PCOS Guideline goes further in one direction people rarely hear. Its recommendation 1.3.2 states that female pattern hair loss and acne in isolation, without hirsutism, are relatively weak predictors of biochemical hyperandrogenism. Hair loss on its own is not strong evidence of high androgens, let alone of PCOS. Excess hair growth in a male pattern is the stronger sign: recommendation 1.3.1 says hirsutism alone should be considered predictive of both.

Two things follow. If you have been given a PCOS diagnosis on hair loss alone, it is fair to ask what else it rested on — the diagnostic criteria are specific. And if you are trying to conceive, the hair and the ovulation need two separate conversations, because they need two different treatments and some of the hair treatments cannot be taken while trying.

Hair follicles in different parts of the body respond to androgens in opposite ways. On the face, chest and abdomen, androgens push fine hair to become coarse and pigmented, which is hirsutism. On the scalp, in a genetically susceptible person, the same androgens shorten the growing phase and shrink the follicle over successive cycles, so hair comes back finer each time. That is why the parting widens and the crown thins rather than bald patches appearing.

It is worth saying that this is distressing on its own terms, not only as a clue to something else. The 2023 guideline makes the point formally at recommendation 1.3.4: clinicians should be aware of the potential negative psychosocial impact of clinical hyperandrogenism, and should treat a woman's report of unwanted hair growth or scalp hair loss as important regardless of how severe it looks to them. If your doctor has waved it away as cosmetic, the guideline is on your side.

For assessment, the guideline's practice point 1.3.7 prefers standardised visual scales — the modified Ferriman-Gallwey score with a photographic atlas for hirsutism, and the Ludwig or Olsen scales for female pattern hair loss. Recommendation 1.3.5 sets the hirsutism threshold at a modified Ferriman-Gallwey score of 4 to 6 depending on ethnicity, and notes that women commonly treat the hair themselves, which makes it look milder in the clinic than it is.

This is the part most pages on PCOS hair loss leave out, and it is the part that changes what you do this month. The medicines used to treat androgen-driven hair problems are either contraceptives themselves or drugs that require contraception.

• Combined oral contraceptive pills are the guideline's first-line medical treatment for hirsutism and irregular cycles in PCOS (recommendation 4.2.1). They also prevent pregnancy. You cannot be on one and trying to conceive at the same time.
• Anti-androgens — the class that includes spironolactone, cyproterone acetate, finasteride, flutamide and bicalutamide (practice point 4.6.5) — carry a specific pregnancy risk. Practice point 4.6.3 says that whenever pregnancy is possible, clinicians must counsel women about the risk of incomplete development of the external genital structures of a male fetus, and that women who can get pregnant should be strongly counselled to use effective contraception.
• The Endocrine Society's 2018 hirsutism guideline states the same rule as a recommendation against: it recommends against anti-androgen monotherapy unless adequate contraception is used.
• Weight-loss injections used off-label for PCOS carry a parallel warning. Practice point 4.5.2 says clinicians should ensure effective contraception is in place when pregnancy is possible in women taking GLP-1 receptor agonists, because pregnancy safety data are lacking.

So the honest position is uncomfortable rather than reassuring. While you are actively trying to conceive, most of the effective medical options for the hair are unavailable to you, and the ones that remain are cosmetic or procedural. That is a real trade-off, and it is yours to make with your doctor rather than one to be talked out of.

No, and nothing in the 2023 guideline suggests otherwise. The treatments listed for hirsutism and hair loss are aimed at the hair. The treatments listed for anovulatory infertility are a separate chapter with a separate first-line drug: recommendation 5.3.1 makes letrozole the first-line pharmacological treatment for ovulation induction in anovulatory women with PCOS and no other infertility factor, and recommendation 5.4.5.1 says letrozole should be used rather than clomiphene citrate to improve ovulation, clinical pregnancy and live birth rates. Practice point 5.3.2 notes letrozole is still off-label for this use in many countries.

A combined pill lowers androgens and can make the hair and skin better while you take it. It does not restore your own ovulation — the bleeds on it are withdrawal bleeds — and it does not improve your fertility. If a page or a clinic tells you the pill will regulate your cycles and improve your fertility prospects at the same time, that is wrong. Which cause of anovulation is yours is the question that decides treatment.

Weight loss is the one intervention that genuinely touches both androgens and ovulation, and it is also the one most often used to postpone treatment. The LIFEstyle randomised trial put 577 infertile women with a BMI of 29 or above into either six months of lifestyle intervention before fertility treatment or prompt treatment. The delayed group had fewer healthy term births: 27.1% versus 35.2%, a rate ratio of 0.77 with a confidence interval of 0.60 to 0.99. Weight is worth working on. Waiting is not automatically worth it.

The 2023 guideline makes no recommendation for any supplement, vitamin or topical oil for female pattern hair loss. On inositol, which is the most commonly sold supplement for PCOS in India, recommendation 4.7.1 says it could be considered based on individual preference, noting limited harm and possible improvement in metabolic measures, but with limited clinical benefit including in ovulation, hirsutism or weight. That is permission, not evidence of effect.

For hirsutism specifically, the Cochrane review of interventions is the largest collection of trials there is, and it is sobering. It pooled 157 randomised trials covering 10,550 women with a mean age of 25. Of those 157 trials, 123 were rated high risk of bias, and the two outcomes that matter most to a patient — her own rating of improvement, and change in quality of life — were addressed in few studies. Adverse events were reported in only half.

There is no source cited here that supports biotin, omega-3, rosemary or peppermint oil, or scalp massage for androgen-driven hair loss, and none was found while writing this. If you want the wider picture on what does and does not change PCOS outcomes, what actually changes the outcome in PCOS covers it.

For facial hirsutism, the guideline is clearest about procedures. Recommendation 4.8.1 says mechanical laser and light therapies should be considered for reducing facial hirsutism and for the related depression, anxiety and quality of life. Recommendation 4.8.2 adds that women with PCOS may need more sessions than women with hirsutism from other causes, which is useful to know before you are quoted a package price. Recommendation 4.8.3 notes adverse effects appear limited in the hands of experienced and suitably qualified providers.

For medical treatment of hirsutism, recommendation 4.6.1 sets the sequence: anti-androgens could be considered, in combination with effective contraception, only if the response is still suboptimal after a minimum of six months of a combined pill or cosmetic therapy. So anti-androgens are a second step after six months, not a starting point.

For scalp hair loss the guideline is quieter, and that silence is itself information: it recommends visual scales for assessing female pattern hair loss but recommends no specific treatment for it. Anything offered for the scalp is extrapolated from the general population, not from PCOS-specific evidence, and is worth asking about on those terms. Drug choice belongs with a dermatologist or endocrinologist who knows you are trying to conceive.

Do not stop or change a prescription because of a web page. Do tell the person who prescribed it whether you are trying to conceive, or might be, because that single fact changes the answer. The guideline's practice point 4.6.3 requires that counselling to happen whenever pregnancy is possible, and the Endocrine Society guideline recommends against anti-androgen monotherapy unless adequate contraception is used.

Reasonable questions: what is this drug for, hair or ovulation; what contraception am I expected to use while I take it; and what is the plan for stopping it if we start trying. If nobody asked whether you were trying, raise it.

Where the cited guidance stops.

• That treating hair loss improves fertility. No source cited here shows that any hair or skin treatment restores ovulation or increases pregnancy rates.
• That hair loss severity predicts how difficult conception will be. Recommendation 1.3.2 points the other way, describing female pattern hair loss in isolation as a relatively weak predictor even of high androgens.
• How much hair regrows once androgens are lowered. The guideline sets a six-month minimum before judging a combined pill's effect on hirsutism and gives no equivalent figure for the scalp.
• Whether any supplement affects female pattern hair loss. The guideline makes no recommendation either way, which is not the same as a negative finding.
• Whether anti-androgens taken before a pregnancy was known about have caused harm in a particular case. The guideline describes a risk to be prevented by contraception, not a measure of risk after exposure. That question belongs with your doctor, urgently and without shame.